Company news

Gilead Sciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023

June 13, 2023

Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma

June 5, 2023

Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

June 4, 2023

Gilead Appoints Cindy Perettie Executive Vice President of Kite

May 15, 2023

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

May 14, 2023

Gilead Sciences to Present at Upcoming Invest...

May 1, 2023

Gilead Sciences Announces First Quarter 2023 Financial Results

April 26, 2023

Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023

April 12, 2023

Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

March 21, 2023

Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

March 20, 2023

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

March 19, 2023

Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV

February 21, 2023

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

February 20, 2023

Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

February 13, 2023

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

February 2, 2023

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

February 1, 2023

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

January 31, 2023

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

January 18, 2023

Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

January 2, 2023

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

December 26, 2022

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

December 8, 2022

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

November 28, 2022

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

November 27, 2022

Gilead's Path to Equitable Global COVID-19 Treatment Access

November 1, 2022

Gilead Sciences Announces Third Quarter 2022 Financial Results

October 26, 2022

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers

October 19, 2022

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

October 16, 2022

Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022

October 12, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

October 10, 2022

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

October 2, 2022

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

September 21, 2022

Gilead Sciences Completes Acquisition of MiroBio

September 19, 2022

Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

September 15, 2022

Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity

September 12, 2022

Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

September 5, 2022

Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

August 21, 2022

Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care

August 16, 2022

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

August 14, 2022

Gilead Sciences to Acquire MiroBio

August 3, 2022

Gilead Sciences Announces Second Quarter 2022 Financial Results

August 1, 2022

Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

July 21, 2022

Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity

July 19, 2022

Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)

July 18, 2022

Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

July 11, 2022

Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

June 27, 2022

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

June 26, 2022

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

June 1, 2022

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

May 1, 2022

Gilead Sciences Announces First Quarter 2022 Financial Results

April 27, 2022

Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

April 24, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.